HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005

TamPub

Näytä suppeat kuvailutiedot

dc.contributor.author Köninki, Katri -
dc.contributor.author Tanner, Minna -
dc.contributor.author Auvinen, Anssi -
dc.contributor.author Isola, Jorma -
dc.date.accessioned 2012-06-17T20:16:40Z
dc.date.available 2012-06-16 13:42:01 -
dc.date.available 2012-06-17T20:16:40Z
dc.date.issued 2009 -
dc.identifier.issn 1465-542X -
dc.identifier.uri http://tampub.uta.fi/handle/10024/66291
dc.description BioMed Central Open access -
dc.description.abstract Introduction Classification of breast cancers according to the HER-2 oncogene status is of central importance in the selection of post-surgical therapies. A decrease in the proportion of HER-2-positive breast cancer has been suspected, but no data on the incidence trends at population level have been reported. Methods We studied the proportion of HER-2-positive breast cancers by chromogenic in situ hybridization (CISH) in three cohorts (years 1982 to 1986 (n = 310), 1989 to 1992 (n = 108), and 2004 to 2005 (n = 713)) in the population of the Pirkanmaa hospital district (approximately 220,000 women). Cancer incidence rates were age-adjusted to the world standard population. Results The proportion of HER-2-positive breast cancer declined from 21.6% (average in 1982 to 1986) to 13.6% (average in 2004 to 2005). However, during the same time period the age-adjusted incidence of all invasive breast cancers had increased by 40%. These opposite trends balanced each other and indicated that the incidence of HER-2-positive breast cancer has remained unchanged (Poisson regression coefficient for time trend 1.000; 95% CI = 0.989 to 1.012). In contrast, the incidence of HER-2-negative cancer showed 2% annual increase (Poisson regression coefficient 1.021, 95% CI = 1.016 to 1.026). Although HER-2-negative cancers were more likely to be diagnosed by mammography screening, the changes were more likely to be explained by etiological risk factors favoring HER-2-negative (and hormone receptor-positive) disease such as menopausal hormone therapy. Conclusions These results document a significant decrease in the proportion of HER-2-positive breast cancer. However, the incidence of HER-2-positive cancer at the population level was found to be unchanged. -
dc.language.iso en -
dc.title HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-552 -
dc.identifier.doi 10.1186/bcr2322 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Lääketieteen bioteknologia | en=Medical biotechnology| -
dc.journal.title Breast Cancer Research -
dc.journal.volume 11 -
dc.journal.number R37 -
dc.journal.volumepagerange 1-6 -
dc.oldstats 62 -

Viite kuuluu kokoelmiin:

Näytä suppeat kuvailutiedot